Oral Micronized Progesterone Dose Conversion: Weekly to Daily

Why the Weekly-to-Daily Conversion Question Comes Up

Women ask this question for a specific reason. Some prescribers start patients on a lower-frequency regimen, sometimes 200 mg twice weekly or 400 mg once weekly, to ease the body into the sedating effect that oral micronized progesterone can cause at higher single doses. Once tolerance is established, or once a woman switches from cyclic to continuous hormone therapy, converting that schedule to a daily milligram dose becomes necessary.

The answer matters clinically. Oral micronized progesterone is not a sustained-release formulation. Each capsule produces a peak serum progesterone level roughly 2 to 4 hours after ingestion, then falls off sharply. That peak-and-trough pattern means spreading the same total weekly dose across seven nightly doses produces meaningfully different tissue exposure than taking it all at once or twice a week. Endometrial protection, which is the core safety function of progesterone in women who have a uterus and are taking estrogen, depends on adequate and consistent progestogenic stimulus throughout the month, not just on weekly totals.

The Math Is Straightforward, the Biology Is Not

The arithmetic is simple: take your total weekly dose and divide by 7.

• 200 mg once weekly = approximately 28.6 mg per day (round to 100 mg nightly, the nearest available strength)
• 400 mg once weekly = approximately 57 mg per day (again, round to 100 mg nightly)
• 200 mg twice weekly (400 mg total) = same calculation, 100 mg nightly
• 200 mg three times weekly (600 mg total) = approximately 86 mg per day (round to 100 mg nightly)

In practice, nearly all continuous daily regimens land at either 100 mg or 200 mg per night, because those are the only capsule strengths commercially available in the United States under the FDA-approved Prometrium labeling.

Why Rounding Up to 100 mg Is Usually Correct

A prescriber rounding from a calculated 28-57 mg/day up to 100 mg/day is not being careless. The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions), published in JAMA in 1995, demonstrated that 200 mg of oral micronized progesterone taken cyclically for 12 days per month provided endometrial protection equivalent to medroxyprogesterone acetate, with a more favorable HDL-cholesterol profile. That 200 mg cyclic dose, averaged across a 28-day cycle, works out to roughly 86 mg per day. The 100 mg continuous nightly dose was subsequently adopted in clinical practice as the closest available approximation that also minimizes sedation. It has become the standard recommended in The Menopause Society (formerly NAMS) position statement on hormone therapy.

How Life Stage Changes the Target Dose

Progesterone dosing is not one-size-fits-all across a woman's reproductive life. The purpose of the progesterone, your endogenous hormone baseline, and your cycle status all affect which dose makes sense.

Reproductive Years (Ages Roughly 18 to 40)

Women in their reproductive years rarely need exogenous oral micronized progesterone for hormone therapy purposes. When it is prescribed in this group, it is usually for luteal phase support, heavy or irregular cycles, or as part of fertility treatment. Doses for luteal phase support in IVF cycles may reach 200 to 400 mg per day vaginally, though that route is distinct from oral use. Oral progesterone for cycle regulation in reproductive-age women is less standardized, and the evidence base is thinner than for postmenopausal hormone therapy. Your prescriber should state clearly what goal the dose is serving.

Perimenopause (Typically Ages 40 to 52, Variable)

Perimenopause is the stage where progesterone dosing gets most complicated, and where many women receive their first prescription. Estrogen levels fluctuate wildly in early perimenopause while progesterone from ovulation becomes intermittent. Women who still have periods but are experiencing irregular cycles, heavy bleeding, or sleep disruption from progesterone insufficiency are often started on cyclic oral micronized progesterone, typically 200 mg for 12 to 14 days per month, timed to the second half of the cycle.

When a perimenopausal woman on a cyclic regimen asks about converting to daily dosing, the answer depends on whether she has reached menopause (12 consecutive months without a period). Switching to continuous daily progesterone before menopause is confirmed may suppress cycle tracking and make it harder to know when menopause has occurred. Most guidelines suggest staying on a cyclic schedule through perimenopause.

Post-Menopause

This is the life stage where continuous daily oral micronized progesterone is most clearly indicated, specifically for women who have a uterus and are using systemic estrogen therapy. The FDA-approved Prometrium label specifies 200 mg per day for 12 days per 28-day cycle (sequential) or 100 mg per day continuously when used with conjugated estrogens. Women without a uterus do not need a progestogen at all, and adding one confers risk without benefit.

Sedation: The Practical Problem That Drives Dosing Schedules

Oral micronized progesterone has a well-documented sedative effect. It is metabolized in the gut and liver to allopregnanolone, a neuroactive steroid that acts on GABA-A receptors, producing a calming and sleep-promoting effect that many women find welcome but that some find disabling the next morning. A study published in Menopause (2022) found that 200 mg nightly significantly improved self-reported sleep quality in perimenopausal and postmenopausal women compared to placebo.

Why Some Prescribers Start Weekly and Titrate Down to Daily

Starting a patient at 200 mg twice weekly, then titrating toward 100 mg nightly, is a strategy some clinicians use to let a woman test her sedation tolerance before committing to daily dosing. The logic is reasonable: a woman who takes 200 mg on a Tuesday night and cannot function on Wednesday morning will know to expect that at 100 mg nightly, the effect will be milder but still present.

Minimizing Next-Day Grogginess

Taking oral micronized progesterone at least 30 minutes before you intend to fall asleep, ideally 2 to 3 hours before if you need to be functional early, tends to reduce next-morning sedation. Taking it with a small amount of food, particularly something containing fat, increases absorption by up to approximately 173% compared to fasting, which means the sedation may be stronger but the endometrial protection is better. Your prescriber needs to know which administration pattern you are using, because the choice affects bioavailability and therefore effective dose.

Sex-Specific Pharmacokinetics: What Makes Oral Micronized Progesterone Different in Women

Progesterone pharmacokinetics in women are directly shaped by hormonal status, which changes the clinical picture in ways that male-default pharmacology texts often miss.

Postmenopausal women have lower endogenous progesterone than premenopausal women, which means exogenous oral micronized progesterone faces less competition at receptor sites. Serum progesterone levels after a 200 mg oral dose in postmenopausal women can reach 3 to 40 ng/mL within 2 to 4 hours, a range so wide that population-level dosing recommendations carry real individual variability. Body weight, liver enzyme activity (particularly CYP3A4, which metabolizes progesterone), and gut transit time all vary between women and affect the conversion calculation.

Women with PCOS may have different progesterone sensitivity and are more likely to have been prescribed oral micronized progesterone for cycle regulation or as part of a hormonal management strategy. The evidence for progesterone-only approaches in PCOS is limited, and most data are derived from studies in which PCOS was not the primary population.

The WomanRx Dose-Conversion Framework below is the clearest clinical summary currently available for the weekly-to-daily conversion question, because the Prometrium label describes only the endpoints (100 mg/day continuous or 200 mg/day cyclic) and does not address intermediate titration schedules.

WomanRx Oral Micronized Progesterone Conversion Table

| Weekly Schedule | Total Weekly mg | Calculated Daily mg | Practical Daily Dose | |---|---|---|---| | 100 mg once weekly | 100 mg | 14.3 mg | 100 mg nightly (round up) | | 200 mg once weekly | 200 mg | 28.6 mg | 100 mg nightly (round up) | | 200 mg twice weekly | 400 mg | 57 mg | 100 mg nightly (round up) | | 200 mg three times weekly | 600 mg | 85.7 mg | 100 mg nightly (round to nearest) | | 200 mg four times weekly | 800 mg | 114 mg | 100 mg nightly (or 200 mg per clinician discretion) |

Note: rounding to 100 mg nightly is appropriate for most continuous hormone therapy indications. Any schedule above 100 mg/day continuously should be explicitly discussed with your prescriber, because higher continuous doses have not been systematically studied for long-term endometrial protection at the population level.

Endometrial Protection: The Non-Negotiable Reason Dose Accuracy Matters

If you have a uterus and you are taking systemic estrogen therapy, progesterone is not optional. Unopposed estrogen causes the uterine lining to grow without the shedding signal that progesterone provides, and that sustained growth is a known pathway to endometrial hyperplasia and endometrial cancer. The PEPI Trial found that 62% of women on unopposed estrogen developed endometrial hyperplasia over three years, compared to fewer than 4% in the oral micronized progesterone arms.

Under-dosing progesterone, whether by converting a weekly dose inaccurately or by taking it inconsistently, creates the same risk as taking no progesterone at all if the under-dose is insufficient to oppose estrogen's proliferative effect. This is why the conversion rounding-up to 100 mg is clinically deliberate, not arbitrary.

Signs That Your Dose May Be Insufficient

• Unexpected uterine bleeding or spotting after you were told to expect none
• Pelvic heaviness or cramping without a clear cause
• A thickened endometrial stripe on ultrasound (above 4 mm in a postmenopausal woman)

Any of these findings warrant a call to your prescriber, not a self-adjusted dose increase.

Who This Dosing Approach Is Right For, and Who It Is Not

Right For

• Postmenopausal women with a uterus who are taking systemic estrogen and want the most body-identical progestogen option
• Perimenopausal women with confirmed progesterone insufficiency (based on symptoms and cycle history, not serum levels alone) who need cyclic support
• Women who tolerated weekly oral micronized progesterone but want the convenience and more consistent endometrial coverage of daily dosing
• Women who have noted improved sleep on weekly progesterone and want that benefit nightly at a lower sedating dose

Not Right For

• Women without a uterus who are taking estrogen-only therapy (no progestogen is needed)
• Women with a confirmed or suspected peanut allergy (Prometrium is manufactured in peanut oil; even patients who report only mild peanut sensitivity should discuss this risk with their allergist and prescriber before using Prometrium)
• Women who are pregnant without specialist direction (see next section)
• Women taking strong CYP3A4 inducers such as rifampin or carbamazepine, which may lower progesterone levels substantially and require dose adjustment

Pregnancy, Lactation, and Contraception

Pregnancy. Oral micronized progesterone is FDA Pregnancy Category not formally assigned under the old letter system (it predates the 2015 reclassification), but the current Prometrium label states that available human data do not indicate an increased risk of major birth defects or miscarriage when used in the first trimester. Progesterone is a naturally occurring hormone and is not considered a classic teratogen. However, Prometrium is not FDA-approved for pregnancy support; its labeling is specific to postmenopausal hormone therapy. Some reproductive endocrinologists prescribe it off-label for luteal phase support in IVF or for recurrent pregnancy loss, typically at doses of 200 mg twice or three times daily vaginally or orally. If you are using Prometrium while trying to conceive or are newly pregnant, tell your reproductive endocrinologist or OB-GYN immediately so they can evaluate whether the dose and route are appropriate for your situation.

Lactation. Progesterone transfers into breast milk. Data from LactMed (NIH) indicate that endogenous progesterone is naturally present in breast milk and that exogenous oral progesterone at typical doses is unlikely to cause harm to a nursing infant. However, high-dose or long-duration use has not been studied in breastfeeding women, and the peanut oil vehicle in Prometrium is a theoretical allergen concern in infants with peanut-allergic family histories. Discuss timing of hormone therapy initiation with your postpartum provider if you are breastfeeding.

Contraception. Oral micronized progesterone at the doses used in menopause hormone therapy (100 to 200 mg/day) is NOT reliable contraception. Perimenopausal women can still ovulate unpredictably. If pregnancy is possible and not desired, use a separate, reliable contraceptive method. Oral micronized progesterone at these doses does not suppress ovulation consistently.

Drug Interactions and Monitoring

Oral micronized progesterone is metabolized primarily through CYP3A4. Drugs that inhibit CYP3A4, including ketoconazole, clarithromycin, and some HIV antiretrovirals, may raise progesterone levels and intensify sedation. Drugs that induce CYP3A4, including rifampin, phenytoin, and St. John's Wort, may reduce progesterone exposure and potentially compromise endometrial protection.

The Prometrium prescribing information also notes that oral micronized progesterone should be used with caution in women with liver impairment, as hepatic metabolism is the primary clearance pathway.

Routine monitoring for most women on standard hormone therapy doses does not require serum progesterone testing. Serum levels vary so widely after oral dosing that a single measurement rarely guides clinical decisions. The better clinical endpoint is symptom response and, for women on estrogen, the absence of abnormal uterine bleeding.

What the Evidence Gap Means for You

Women have been historically underrepresented in pharmacokinetic trials, and oral micronized progesterone is no exception. The PEPI Trial enrolled 875 women and remains one of the largest RCTs specifically examining progesterone formulations in postmenopausal hormone therapy, yet it was conducted in the early 1990s and its findings have been extrapolated broadly to populations and dose schedules not directly studied. The 2022 Menopause Society Hormone Therapy Position Statement acknowledges that data on optimal progesterone formulation, dose, and duration remain incomplete, particularly for women under 50 and those with complex medical histories.

As WomanRx reviewer Rachel Goldberg, MD, puts it: "The weekly-to-daily conversion question is one I hear constantly in practice, and the honest answer is that the pharmacokinetic data to nail down the exact equivalent dose just don't exist for most intermediate schedules. We round to 100 mg nightly because that's the studied endpoint and the available capsule size, not because someone ran a rigorous bioequivalence trial comparing 400 mg weekly to 100 mg daily. Women deserve to know that distinction."

Talking to Your Prescriber About Switching Schedules

Before you change your progesterone schedule, write down three things: your current total weekly dose in milligrams, the reason you want to switch (convenience, better sleep, concern about inconsistent coverage), and any symptoms you have noticed on your current regimen. Bring that list to your appointment or send it through your telehealth portal.

Your prescriber should confirm your uterine status, your concurrent estrogen dose and type, and any medications that could interact with CYP3A4 before finalizing a new schedule. A follow-up check-in at 8 to 12 weeks, looking specifically for breakthrough bleeding or worsening sedation, is reasonable clinical practice when any dose or schedule change is made.

If you are on a compounded progesterone rather than FDA-approved Prometrium, the conversion math may differ because compounded formulations have variable bioavailability and are not subject to the same manufacturing consistency standards. That distinction is worth raising explicitly with your prescriber.